How do I calculate the appropriate dosing of Humulin 70/30 (human insulin) for an adult with type 2 diabetes?

Calculating Humulin 70/30 Dosing for Type 2 Diabetes

For adults with type 2 diabetes requiring premixed insulin, start Humulin 70/30 at 0.3 units/kg/day divided into two doses (2/3 before breakfast, 1/3 before dinner), administered 30-45 minutes before meals. 1

Initial Dosing Strategy

The FDA-approved approach for Humulin 70/30 requires individualized dosing based on metabolic needs and blood glucose monitoring 1. However, practical starting points exist:

Weight-Based Calculation

• Starting dose: 0.3 units/kg/day when adding insulin to existing therapy (augmentation approach) 2
• Alternative: 0.6-1.0 units/kg/day if using insulin as replacement therapy 2
• For most patients initiating premixed insulin, use the lower augmentation dose initially

Fixed-Dose Starting Point

• Alternative approach: 6-10 units twice daily targeting daytime or postprandial hyperglycemia 3
• This simpler method works well when weight-based calculations are impractical

Dose Distribution

When using twice-daily premixed insulin regimens 4:

• 2/3 of total daily dose before breakfast
• 1/3 of total daily dose before dinner

Critical timing requirement: Administer 30-45 minutes before meals 1 — this is non-negotiable for Humulin 70/30 due to its pharmacokinetic profile.

Titration Algorithm

Increase by 2 units every 3 days until fasting plasma glucose targets are reached without hypoglycemia 4. The 2025 ADA Standards of Care provide this evidence-based titration schedule as the preferred approach.

Alternative Titration Approach

A more aggressive prophylactic titration based on fasting glucose 3:

• Fasting glucose <4.4 mmol/L (79 mg/dL): Decrease by 2 units
• 4.4-7.0 mmol/L (79-126 mg/dL): No change
• 7.1-10.0 mmol/L (128-180 mg/dL): Increase by 2 units
• >10.0 mmol/L (>180 mg/dL): Increase by 4 units

Or increase by 1 unit/day until fasting glucose of 5.5 mmol/L (99 mg/dL) is reached 3.

Expected Outcomes

• Final doses typically range 40-70 units/day 3
• HbA1c reduction of 1.5-2.5% is achievable 3
• Approximately 50% of patients achieve HbA1c ≤7% 3
• Weight gain around 3 kg over 6 months is expected 3

Critical Limitations of Premixed Insulin

The proportion of rapid-acting (30%) and intermediate-acting (70%) insulin is fixed in Humulin 70/30, making independent adjustment of basal or prandial components impossible 1. This is the major pitfall — if a patient needs different basal versus prandial coverage, premixed insulin becomes problematic.

When Premixed Insulin Fails

If A1C remains above goal on twice-daily premixed insulin 4:

• Consider converting to basal-bolus regimen with separate insulins
• Add GLP-1 receptor agonist (preferred over further insulin intensification)
• Consider fixed-ratio combination products (IDegLira or iGlarLixi)

Dosage Adjustments Required

Dose requirements change with 1:

• Physical activity changes (increased activity = lower dose needed)
• Meal pattern changes (timing or macronutrient content)
• Renal or hepatic dysfunction (lower doses needed)
• Acute illness (higher doses typically needed)

Hypoglycemia Management

If hypoglycemia occurs: Determine cause; if no clear reason, lower the corresponding dose by 10-20% 4. This applies to both morning and evening doses independently.

Important Safety Considerations

• Never mix Humulin 70/30 with other insulins or diluents 1
• Subcutaneous administration only — never IV, IM, or in insulin pumps 1
• Rotate injection sites within the same region (abdomen, thigh, upper arm, buttocks) to prevent lipodystrophy 1
• Visual inspection required: Should appear uniformly cloudy after mixing; discard if particulate matter present 1

Clinical Context: When to Use Premixed Insulin

The 2025 ADA guidelines position premixed insulin as an option when intensifying from basal insulin 4, but GLP-1 receptor agonists are now preferred over insulin intensification for most patients not at goal on basal insulin. Premixed insulin remains useful for:

• Patients who cannot afford or tolerate GLP-1 RAs
• Those requiring simplified regimens (fewer injections than basal-bolus)
• Patients with significant postprandial hyperglycemia on basal insulin alone

Research shows premixed insulin provides superior glycemic control compared to sliding scale insulin 5 and can be effective when transferred from self-mixed regimens 6. However, three-times-daily rapid-acting premixed formulations (like Mix50) provide better control than twice-daily 70/30 7, though this increases injection burden.